Stay updated on Brexanolone in COVID-19 ARDS Clinical Trial
Sign up to get notified when there's something new on the Brexanolone in COVID-19 ARDS Clinical Trial page.

Latest updates to the Brexanolone in COVID-19 ARDS Clinical Trial page
- Check3 days agoChange DetectedNew screenshot shows a reorganized layout and updated styling of the page header and sections. Core study data such as title, eligibility criteria, locations, enrollment, and primary outcomes appear unchanged.SummaryDifference0.5%

- Check11 days agoNo Change Detected
- Check32 days agoChange DetectedUpdated status notice and version to v3.2.0, replacing v3.1.0; added information about government funding lapse and operating status, and where to find details.SummaryDifference5%

- Check39 days agoChange DetectedUpdated page now shows Revision: v3.1.0 and removes several drug-safety topic sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs).SummaryDifference0.6%

- Check54 days agoChange DetectedRevision updated to v3.0.2 (replacing v3.0.1). The Back to Top UI element has been removed.SummaryDifference0.3%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important elements.SummaryDifference0.3%

- Check68 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as new topics related to drug safety and post-COVID conditions. However, many previous topics and specific drug information have been removed, indicating a shift in focus.SummaryDifference7%

Stay in the know with updates to Brexanolone in COVID-19 ARDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brexanolone in COVID-19 ARDS Clinical Trial page.